Infectious Diseases Self‐Assessment Program (IDSAP) Book 1: PK/PD in Special Populations and Antimicrobial Prophylaxis (Cert # L209207)

ACPE Numbers: Various – see listing below
Pre‐Sale Date: 04/15/2020
Content Release Date: 05/15/2020
Expiration Dates: 11/16/2020
Activity Type: Application‐based
CE Credits: 13.5 hours (BPS and ACPE)
Activity Fee: $75 (ASHP member); $110 (non‐member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health‐System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education

Target Audience

The target audience for IDSAP 2020 Book 1 (PK/PD in Special Populations and Antimicrobial Prophylaxis) is board certified and advanced‐level infectious disease pharmacists involved in evidence‐based management strategies for the prevention and management of drug‐resistant gram‐negative infections.

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 3 learning modules (see table below) and provides up to TBD hours of continuing pharmacy education and/or recertification credit.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well‐established standards of practice in the specialty practice.

These activities are part of the ACCP and ASHP and professional development program for BCIDP recertification approved by the BPS.

Recertification Credit*

Board-certified pharmacists are eligible to receive up to TBD hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

IDSAP 2020 Book 1: PK/PD in Special Populations II

0217-9999-20-018-H01-P

4.5

66%

IDSAP 2020 Book 1: PK/PD in Special Populations II

0217-9999-20-019-H01-P

6.0

73%

IDSAP 2020 Book 1: PK/PD in Special Populations III

0217-9999-20-118-H01-P

3.0

75%

 

Learning Objectives

IDSAP 2020 Book 1: PK/PD in Special Populations I
ACPE Number: 0217-9999-20-118-H01-P

  • Evaluate the impact of critical illness‐related pharmacokinetic and pharmacodynamic differences antimicrobial exposures and dosing requirements in critically ill patients.
  • Design and justify various alternative dosing strategies for commonly used antimicrobials that can be applied in critically ill patients based on current pharmacokinetic and pharmacodynamic data.
  • Design and justify various antimicrobial dosing strategies for subgroups of patients in the ICU (e.g., augmented renal clearance, renal replacement therapy, and extracorporeal membrane oxygenation patients).
  • Evaluate and assess the latest pharmacokinetic and pharmacodynamic data presented to b applied in clinical decisionmaking.
  • Assess for various pharmacodynamic endpoints associated with optimal antimicrobial activity.
  • Justify the implementation and/or creation of therapeutic drug monitoring services.
  • Distinguish between calculations to appropriately determine patient‐specific pharmacokinetic parameters.
  • Compare and contrast the benefits of various dosing strategies for antimicrobials such as vancomycin and aminoglycosides.
  • Assess serum concentrations of medications that require therapeutic drug monitoring and make appropriate recommendations for dose adjustment.

IDSAP 2020 Book 1: PK/PD in Special Populations II
ACPE Number: 0217-9999-20-019-H01-P

  • Evaluate published evidence regarding optimal antimicrobial prophylactic regimens and explain the role of various antimicrobial prophylactic treatment plans.
  •  For a given patient, develop an antimicrobial plan for the prevention of surgical site infection.
  • Assess patients for risk factors associated with an increased risk of surgical site infections.
  • Evaluate the role of topical antibiotics for the prevention of surgical infections.
  • Develop an understanding of recent epidemiologic changes, etiology, risk factors, and clinical presentation of common vaccine‐preventable diseases.
  • Distinguish between the various available influenza, pneumococcal, herpes zoster, tetanus-diphtheria pertussis, measles mumps rubella, and hepatitis vaccines.
  • Evaluate the impact of influenza and pneumococcal vaccines on antibiotic resistance.
  • Design a patient‐specific immunization regimen based on age, risk factors, and comorbid conditions.
  • Justify the role of the pharmacist in addressing Sedo‐science.
  • Distinguish between the types of bioanalytical methods and assess the advantages and disadvantages of each method.
  • Evaluate drug concentrations based on the approved FDA procedures and protocols.
  • Develop validated assays according to the FDA standards.
  • Apply common procedures and workflow for drug concentration quantification.
  • Distinguish between procedures needed for clinical and research‐only samples.

IDSAP 2020 Book 1: PK/PD in Special Populations III
ACPE Number: 
0217-9999-20-118-H01-P

  • Assess for technical and regulatory challenges around precision dosing clinical decision‐support systems (CDSS), ability to classify tools.
  • Apply the concepts of Bayesian dosing tools, exemplified using vancomycin
  • Assess appropriateness and limitations of literature PK models, and how to apply in individual patient cases.
  • Evaluate the use of dosing tools in individual patient cases.
  • Evaluate the societal, clinical, and economic burden of antimicrobial resistance and the importance of antibiotics to healthcare.
  • Assess the various stages of drug development while providing timelines in each stage and how the FDA is involved in each stage of R&D.
  • Evaluate the regulatory process for drugs from the FDA perspective.
  • Distinguish between the various legislative and funding approaches in aiding with antimicrobial development and approval.
  • Evaluate novel regulatory processes to aid in the development and approval of antibiotics.

Planners, Presenters, and Reviewers

Professor and Director, Pharmacometrics
Center of Excellence
Chicago College of Pharmacy, Department of Pharmacy Practice
College of Graduate Studies, Department of Pharmacology Midwestern University
Infectious Diseases Pharmacist
Northwestern Medicine Department of Pharmacy
Chicago, Illinois

Associate Professor of Medicine
Division of Infectious Diseases
Duke University School of Medicine Director of Operations
Duke Antimicrobial Stewardship Outreach Network (DASON)
Durham, North Carolina
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Infectious Diseases Pharmacist
Hospital Pharmacy Services
University of Illinois Hospital and Health Sciences System Chicago, Illinois
Pharm, B.Pharm (Hons)
Clinical Research Pharmacist
University of Queensland Centre for Clinical Research
The University of Queensland
Royal Brisbane and Women’s Hospital Brisbane, Queensland
Australia
Research Assistant Professor
Infectious Disease Pharmacokinetics Laboratory
University of Florida
Gainesville, Florida
Clinical Pharmacist Medical ICU/Pulmonary Department of Pharmacy Services
University of Kentucky
Assistant Adjunct Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky
College of Pharmacy
University of Florida
Gainesville, Florida
Professor of Pharmacy Practice
Department of Pharmacy Practice
Palm Beach Atlantic University
Gregory School of Pharmacy
West Palm Beach, Florida
Clinical Pharmacy Specialist
Department of Pharmacy Services
Wellington Regional Medical Center
Wellington, Florida
Clinical Coordinator – Neuroscience-Pulmonary/Critical Care
Department of Pharmacy Services
UKHealthCare, University of Kentucky
Associate Adjunct Professor, Pharmacy
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky
Head of Clinical Applications
InsightRX
San Francisco, California
Chief Scientific Officer
InsightRX
San Francisco, California
Infectious Diseases Researcher and Consultant
Infectious Diseases Antimicrobial Stewardship
Expert Stewardship, Inc.
Newport Beach, California
Infectious Diseases/Antimicrobial Stewardship Pharmacist
Department of Quality – Infection Prevention and Patient Safety
Stanford Health Care
Stanford, California
Infectious Diseases/Antimicrobial Stewardship Pharmacist
Department of Quality – Infection Prevention and Patient Safety
Stanford Health Care
Stanford, California
Professor
Infectious Disease Pharmacokinetics Laboratory
University of Florida
Gainesville, Florida
Professor
Department of Pharmacy Practice
Regis University
Denver, Colorado
Professor of Pharmacy and Medicine & NHMRC
Practitioner Fellow
University of Queensland
Centre for Clinical Research
The University of Queensland
Pharmacist Consultant
Pharmacy Department
Royal Brisbane and Women’s Hospital
Brisbane, Queensland
Australia
Melody L. Berg, Pharm.D., MPH, BCPS
Senior Content Management Consultant
Clinical Drug Information
Wolters Kluwer
Indianapolis, Indiana
Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS
Clinical Associate Professor
Department of Clinical and Administrative Pharmacy
University of Georgia
College of Pharmacy
Infectious Diseases Clinical Specialist
St. Joseph’s/Candler Health System, Inc.
Savannah, Georgia
Brad J. Crane, Pharm.D., BCPS-AQ
Infectious Diseases Clinical Pharmacy Specialist, Antimicrobial Stewardship
Department of Pharmacy
Blount Memorial Hospital
Maryville, Tennessee
Carmen M. Faulkner-Fennell, Pharm.D., BCPS, BCIDP Clinical Pharmacy Specialist, Antimicrobial Stewardship
Department of Pharmacy
Prisma Health-Upstate
Greenville, South Carolina
Islam M. Ghazi, Pharm.D., M.Sc., BCPS, BCACP
Assistant Professor of Clinical Pharmacy
Department of Pharmacy Practice and Pharmacy Administration
Philadelphia college of Pharmacy/University of the Sciences
Philadelphia, Pennsylvania
Miki A. Goldwire, Pharm.D., MS, BCPS
Professor and Director of Drug Information
School of Pharmacy
Regis University
Denver, Colorado
Alan E. Gross, Pharm.D., BCPS, BCIDP
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Infectious Diseases Pharmacist
Hospital Pharmacy Services
University of Illinois Hospital and Health Sciences System
Chicago, Illinois
Lynne C. Krop, Pharm.D., BCPS-AQ Infectious Diseases
Pharmacy Clinical Coordinator
Infectious Diseases Specialist
Department of Pharmacy
BayCare Health/Morton Plant Hospital
Clearwater, Florida
Davey Legendre, Pharm.D., MBA, BCPS-AQ Infectious Diseases
Regional Vice President, Clinical Infectious Diseases
Department of Clinical Services
Comprehensive Pharmacy Services
Woodstock, Georgia
Conan MacDougall, Pharm.D., MAS, BCPS, BCIDP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco
School of Pharmacy
San Francisco, California
Cynthia T. Nguyen, Pharm.D., BCPS-AQ Infectious Diseases, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Department of Pharmacy
University of Chicago Medicine
Chicago, Illinois
David E. Nix, Pharm.D., BCPS
Professor
Program Director, PGY2 Infectious Disease Residency
Department of Pharmacy Practice and Science
The University of Arizona College of Pharmacy
Tucson, Arizona
Ronnie Ozuna, Pharm.D., BCPS
Assistant Dean
Assistant Clinical Professor
University of Houston College of Pharmacy
Pharmacy Clinical Coordinator
DHR Health Houston, Texas
Saira Rab, Pharm.D., BCPS, BCIDP, AAHIVP
Infectious Diseases Clinical Pharmacist Specialist
Department of Pharmacy and Medical
Nutrition Grady Health System
Atlanta, Georgia
Melissa Ruble, Pharm.D., BCPS
Assistant Professor
Pharmacotherapeutics and Clinical Research Department
University of South Florida Taneja
College of Pharmacy
Tampa, Florida
Clare L. Tolley, Ph.D., MPharm, PGCert, FHEA, GPhC
Research Associate/Honorary Pharmacist
Population Health Sciences institute and School of Pharmacy
Newcastle University
Newcastle upon Tyne, England
Lynn Wardlow, Pharm.D., MBA, MS, BCPS, BCIDP
Specialty Practice Pharmacist, Infectious Diseases
Department of Pharmacy
The Ohio State University
Wexner Medical Center
Columbus, Ohio
Professor
College of Pharmacy, Rady Faculty of Health Sciences
University of Manitoba
Winnipeg, Manitoba Canada

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the PK/PD in Special Populations and Antimicrobial Prophylaxis I chapters:

Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases/HIV
Antimicrobial Stewardship Program Pharmacy Director
Veterans Affairs Medical Center
West Palm Beach, Florida
Clinical Assistant Professor of Pharmacy Practice
University of Florida College of Pharmacy
Gainesville, Florida
Ralph H. Raasch, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy (retired)
Division of Practice Advancement and Clinical Education
Eshelman School of Pharmacy
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the PK/PD in Special Populations and Antimicrobial Prophylaxis II chapters:

Mary Wun-Len Lee, Pharm.D., FCCP, BCPS
Vice President and Special Assistant to the President
Midwestern University
Professor of Pharmacy Practice
Chicago College of Pharmacy
Downers Grove, Illinois
Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases/HIV
Antimicrobial Stewardship Program Pharmacy Director
Veterans Affairs Medical Center
West Palm Beach, Florida
Clinical Assistant Professor of Pharmacy Practice
University of Florida
College of Pharmacy
Gainesville, Florida
Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGP
Clinical Professor
Department of Pharmacy Practice and Translational Research
University of Houston
College of Pharmacy
Houston, Texas


The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the PK/PD in Special Populations and Antimicrobial Prophylaxis III features:

Ralph H. Raasch, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy (retired)
Division of Practice Advancement and Clinical Education
Eshelman School of Pharmacy
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, the American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Consultancies: Christopher M. Bland (Merck, Biomerieux); Mark Goldberger (Bristol Myers, Carb-X); Ron Keizer (Certara); Conan MacDougall (Paratek Pharmaceuticals); Jason Roberts (Accelerate Diagnostics, Biomerieux, Bayer);
  • Stock Ownership: Jonathan Faldasz (InsightRX); Mark Goldberger (Bristol Myers Squbb, AbbVie, Abbott); Ron Keizer (InsightRX, Pirana Consulting); Ravina Kullar (Merck, Gilead Sciences);
  • Grants: Christopher M. Bland (ALK Abello, Inc., Merck); Islam M. Ghazi (Merck and Co, Achaogen, Astelas); Lynne C. Krop (Society of Infectious Diseases Pharmacists); Charles Arthur Peloquin (Jacobus Pharmaceuticals) ; Jason Roberts (MSD, The Medicines Company, Cardeas Pharma); Sheryl A. Zelenitsky (Kidney Foundation of Canada, Canadian Society of Hospital Pharmacists Foundation, Pfizer Canada Inc.)
  • Honoraria: Christopher M. Bland (Merck, Tetraphase); Elias B. Chahine (Merck, Paratek Pharmaceuticals); Jason Roberts (MSD);
  • Other: Jonathan Faldasz  (employed by InsightRX); Ron Keizer (employed by InsightRX); David Nix (spouse or significant other employed by Celerion)

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development

These activities were developed by ACCP and ASHP.